人甲狀腺未分化癌細(xì)胞（anaplastic thyroid carcinoma, ATC），未分化，取材于女性患者。經(jīng)無支原體/STR鑒定入庫。

動物種別：人

組織來源 ：甲狀腺

形態(tài)：成纖維細(xì)胞樣，貼壁生長

培養(yǎng)基配方：

90%1640(MD0200)+10%胎牛血清(SD0200)+G/A (SD0038)

完全培養(yǎng)基：1640完全培養(yǎng)基（MD0201）

氣相：空氣，95%；二氧化碳，5%。 溫度：37℃。

凍存條件：基礎(chǔ)培養(yǎng)基+5%DMSO+20%FBS(SD0200)

完全凍存液：免程序降溫細(xì)胞凍存液（低血清）(SD0001)

聲明：產(chǎn)品僅科研使用。

PubMed=8121182; DOI=10.1002/jso.2930550209

Yoshida A., Asaga T., Masuzawa C., Kawahara S., Yanoma S., Harada M., Okamoto T.

Production of cytokines by thyroid carcinoma cell lines.

J. Surg. Oncol. 55:104-107(1994)

PubMed=8176927; DOI=10.1002/jso.2930550308

Yoshida A., Asaga T., Masuzawa C., Kawahara S.

Alteration of tumorigenicity in undifferentiated thyroid carcinoma cells by introduction of normal chromosome 11.

J. Surg. Oncol. 55:170-174(1994)

PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3

Satake S., Sugawara I., Watanabe M., Takami H.

Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.

Cancer Lett. 116:33-39(1997)

PubMed=16924234; DOI=10.1038/sj.onc.1209899

Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.

A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.

Oncogene 26:1178-1187(2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102

Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

Patent=US8029793

Yoshida A., Yanoma S., Hirose F.

Methods for inhibiting cell proliferation.

Patent number US8029793, 04-Oct-2011

PubMed=23833040; DOI=10.1210/jc.2013-2383

Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953

Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.

Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

Clin. Cancer Res. 25:3141-3151(2019)